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A B S T R A C T
First generation drug-eluting stents have considerably reduced in-stent restenosis and broadened
the applications of percutaneous coronary interventions for the treatment of coronary artery disease.
The polymer is an integral part of drug-eluting stents in that, it controls the release of an antiproliferative
drug. The main safety concern of first generation drug-eluting stents with permanent polymers—stent
thrombosis—has been caused by local hypersensitivity, delayed vessel healing, and endothelial
dysfunction. This has prompted the development of newer generation drug-eluting stents with
biodegradable polymers or even polymer-free drug-eluting stents. Recent clinical trials have shown the
safety and efficacy of drug-eluting stents with biodegradable polymer, with proven reductions in very
late stent thrombosis as compared to first generation drug-eluting stents. However, the concept of using
a permanent metallic prosthesis implies major drawbacks, such as the presence of a foreign material
within the native coronary artery that causes vascular inflammation and neoatherosclerosis, and also
impedes the restoration of the vasomotor function of the stented segment. Bioresorbable scaffolds have
been introduced to overcome these limitations, since they provide temporary scaffolding and then
disappear, liberating the treated vessel from its cage. This update article presents the current status of
these new technologies and highlights their future perspectives in interventional cardiology.
 2012 Sociedad Espan˜ola de Cardiologı´a. Published by Elsevier Espan˜a, S.L. All rights reserved.
Avances en el tratamiento mediante intervencio´n coronaria percuta´nea: el stent
del futuro
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R E S U M E N
Los stents liberadores de fa´rmacos de primera generacio´n han reducido considerablemente las
reestenosis en el stent y han ampliado las aplicaciones de las intervenciones coronarias percuta´neas en el
tratamiento de la enfermedad coronaria. El polı´mero es parte integrante de los stents liberadores de
fa´rmacos, ya que controla la liberacio´n de un fa´rmaco antiproliferativo. La principal preocupacio´n
respecto a los stents liberadores de fa´rmacos de primera generacio´n con polı´meros permanentes—la
trombosis del stent—se ha debido a la hipersensibilidad local, la cicatrizacio´n tardı´a del vaso y
la disfuncio´n endotelial. Esto ha llevado al desarrollo de stents liberadores de fa´rmacos de nueva
generacio´n con polı´meros biodegradables o incluso sin polı´mero. En ensayos clı´nicos recientes se ha
observado la seguridad y la eficacia de los stents liberadores de fa´rmacos con polı´mero biodegradable,
que han mostrado una reduccio´n demostrada de la trombosis de stent muy tardı´a, comparados con los
de primera generacio´n. Sin embargo, el concepto de utilizar pro´tesis meta´licas permanentes tiene
importantes inconvenientes, como la presencia de un cuerpo extran˜o en el interior de la arteria coronaria
nativa, que causa inflamacio´n vascular y neoaterosclerosis e impide tambie´n el restablecimiento de la
funcio´n vasomotora del segmento tratado con el stent. Para superar esas limitaciones, se han introducido
las estructuras de base bioabsorbible, que proporcionan un armazo´n temporal y luego al desaparecer
liberan el vaso tratado de la jaula que le imponı´an. En este artı´culo de puesta al dı´a se presenta el estado
actual de estas nuevas tecnologı´as y se resaltan sus perspectivas futuras en cardiologı´a intervencionista.
 2012 Sociedad Espan˜ola de Cardiologı´a. Publicado por Elsevier Espan˜a, S.L. Todos los derechos reservados.* Corresponding author: Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Ba583, Dr. Molewaterplein 40, 3015 GD, Rotterdam,
The Netherlands.
E-mail address: p.w.j.c.serruys@erasmusmc.nl (P.W. Serruys).
1885-5857/$ – see front matter  2012 Sociedad Espan˜ola de Cardiologı´a. Published by Elsevier Espan˜a, S.L. All rights reserved.
http://dx.doi.org/10.1016/j.rec.2012.12.009
Abbreviations
BMS: bare metal stent
BRS: bioresorbable scaffold
DES: drug-eluting stent
LLL: late lumen loss
MACE: major adverse cardiac events
MI: myocardial infarction
SES: sirolimus-eluting stent
ST: stent thrombosis
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Coronary stents were first developed in the mid 1980s to
overcome the inherent limitations of balloon angioplasty, including
elastic recoil and vessel closure in the acute phase, as well as
constrictive remodeling and restenosis in the late phase.1–3 In the
1990s, this technology became widely accepted as a promising
treatment strategy for patients with coronary artery disease after
the landmark Belgian Netherlands Stent trial, which demonstrated
the superiority of the bare metal stent (BMS) over balloon
angioplasty.4 Although coronary stenting improved angiographic
results and clinical outcomes, neointimal hyperplasia and restenosis
continued to be major limitations of this technology.5 In order to
minimize neointimal hyperplasia and thereby reduce repeat
revascularization, drug-eluting stents (DES) were developed. Early
pivotal trials of the first generation DES showed excellent results
with respect to the reduction of in-stent restenosis, such that they
rapidly replaced BMS.6,7 In the year 2006, safety concerns were
raised with DES following reports linking their use to an increased
risk of stent thrombosis (ST).8,9 First generation DES, with
permanent polymers, have been associated with delayed endothe-
lialization, endothelial dysfunction, and local hypersensitivity
reactions, resulting in an increased risk of ST and the need for
prolongation of dual antiplatelet therapy.10,11
Newer generation DES, with thinner struts and more biocom-
patible polymers, have considerably improved their safety
profile.12–15 However, concerns still persist over the presence of
durable polymers, as evidence from animal and human studies still
suggest that these durable polymers may cause persistent arterial
wall inflammation and delayed vascular healing, both of which
may subsequently have a potential role in precipitating ST and
delayed in-stent restenosis (ie, late catch-up phenomenon).16
Newer generation DES, coated with biodegradable polymers, offer
the attractive combination of controlled drug elution in parallel
with biodegradation of the polymer into inert monomers. After the
completion of biodegradation, only a ‘‘BMS’’ remains, thereby
reducing the long-term risks associated with the presence of a
permanent polymer.17 An extension of this concept has brought
the development of newer DES that are completely free of polymer,
or come with novel coatings. In addition, bioresorbable metallic
(ie, magnesium) and polymeric scaffolds have been developed,
which initially safeguard the patency of the treated vessel and then
disappear. The aim of this article is to review new stent
technologies that are currently undergoing clinical investigation
and discuss their future perspectives in interventional cardiology.
NEW GENERATION METALLIC DRUG ELUTING STENT
Drug Eluting Stent With Biodegradable Polymers
Biodegradable polymeric coatings facilitate drug delivery to the
vessel wall and are then resorbed without any long-term sequelae.Since their introduction in the year 2004,18 many DES with
biodegradable polymers have been developed, particularly after it
was hypothesized that this technology would potentially reduce
the risk of very late ST (VLST), an adverse event which has been
associated with durable-polymer DES. The randomized ISAR-TEST 4
trial was conducted to test the noninferiority of a biodegradable-
polymer rapamycin-eluting stent (RES; Yukon Choice PC, Translu-
mina; Hechingen, Germany) to a durable-polymer DES (ie, the first
generation Cypher sirolimus-eluting stent [SES] or the second
generation Xience V everolimus-eluting stent [EES]), with respect to
clinical outcomes. A total of 2603 patients were enrolled in the trial.
At 3-year follow-up, there were no significant differences in a
composite of cardiac death, target-vessel myocardial infarction (MI),
and target lesion revascularization (TLR) (RES 20.1% vs DES 20.9%,
P=.59), as well as the incidence of definite/probable ST (RES 1.4% vs
DES 1.9%, P=.51).19 Longer-term clinical follow-up is required to
evaluate the potential superiority of RES over the traditional DES in
reducing the risk of VLST.
Biolimus-eluting Stent With Biodegradable Polymer
Biolimus A9 is a semisynthetic limus-drug designed for stent
application which has a similar potency to sirolimus, but is
10 times more lipophilic. It is immersed at a concentration of
15.6 mg/mm into a polylactic acid biodegradable polymer that
covers the abluminal stent surface. Polylactic acid is coreleased
with biolimus and completely metabolized into carbon dioxide
and water over 6 months to 9 months. The stainless steel stent
platform has a strut thickness of 112 mm, with a quadrature link
design. Currently, the stent platforms utilizing this technology are
the BioMatrix Flex (Biosensors Inc.; Singapore), NOBORI (Terumo
Corp.; Tokyo, Japan), and Axxess (Biosensors Inc.).
In the LEADERS trial, the BioMatrix stent was shown to be
noninferior to the first generation durable-polymer Cypher SES,
with respect to a composite end point of cardiac death, MI, and
ischemia-driven target vessel revascularization at 12-month
follow-up (BioMatrix 10.6% vs Cypher 12.0%, P=.37).20 This
noninferiority has recently been confirmed at 5-year follow-
up.21 Importantly, the BioMatrix stent showed a significantly
lower incidence of definite VLST at 5-year follow-up (hazard
ratio=0.26 [0.10-0.68]). A pooled data analysis of the randomized
ISAR-TEST 3, ISAR-TEST 4, and LEADERS trials also showed that the
DES with biodegradable polymers were associated with a lower
risk of VLST as well as MI compared to the Cypher SES.22 The
LEADERS trial not only provided the first evidence of improved
clinical outcomes compared to the first generation DES, but is also
the proof of concept in terms of biodegradable-polymer DES.
Everolimus-eluting Stent With Biodegradable Polymer: SYNERGY
Stent
The SYNERGY stent (Boston Scientific; Natick, Massachusetts,
United States) consists of a thin-strut (74 mm), platinum-chromi-
um platform that delivers everolimus from a bioabsorbable poly-
lactide-co-glycolide polymer applied to the abluminal surface.
In the randomized, EVOLVE trial, the safety and efficacy of
2 dose formulations (standard dose [SD], 113 mg/20 mm, and half
dose [HD], 56 mg/20 mm) of the SYNERGY stent were compared to
the durable-polymer PROMUS Element EES (Boston Scientific).23 A
total of 291 patients were randomly assigned in a 1:1:1 ratio to
SYNERGY, SYNERGY HD, and EES. The primary clinical endpoint
was the 30-day rate of target lesion failure (TLF), defined as a
composite of cardiac death, MI related to the target vessel, and TLR.
TLF occurred in 3.1%, 1.1%, and 0% of patients in the SYNERGY,
SYNERGY HD, and EES groups, respectively. The 6-month in-stent
Table 1
Overview of Drug-eluting Stents With a Biodegradable Polymer Under Clinical Investigation or Already Available Outside the United States
Drug-eluting stent,
manufacturer
Drug, dosage Stent
platform
Strut/coating
thickness,
mm
Polymer Biodegradation
of polymer,
months
Drug release
kinetics %
(days)
Study, no.
of patients
Angiographic
follow-up,
months
In-stent late
loss, mm
Binary
restenosis, %
Current status
BioMatrix Flex
(Biosensors)
Biolimus A9
(15.6mg/mm)
SS 112/10 Abluminal PLA 6-9 45 (30) LEADERS (857) 9 0.13 20.9 CE approved
NOBORI (Terumo) Biolimus A9
(15.6mg/mm)
SS 112/10 Abluminal PLA 6-9 45 (30) NOBORI 1 (153) 9 0.11 0.7 CE approved
Axxess (Biosensors) Biolimus A9
(22mg/mm)
Nitinol 152/15 Abluminal PLA 6-9 45 (30) DIVERGE (302) 9 MB, 0.29;
SB 0.29
MB, 2.3;
SB, 4.8
CE approved
Supralimus (Sahajanand
Medical)
Sirolimus
(125mg/19 mm)
SS 80/4-5 PLLA-PLGA -
PCL-PVP
7 100 (48) SERIES I (100) 6 0.09 0.0 CE approved
Infinnium (Sahajanand
Medical)
Paclitaxel
(122mg/19 mm)
SS 80/4-5 PLLA-PLGA -
PCL-PVP
7 50 (9-11) SIMPLE II (111) 9 0.54 8.3 CE approved
BioMime (Meril Life
Science)
Sirolimus
(1.25mg/mm2)
Co-Cr 65/2 PLLA+PLGA N/A 100 (30) MERIT II (242) 8 0.11 5.0 CE approved
Orsiro (Biotronik) Sirolimus
(1.4mg/mm2)
Co-Cr 60/7 PLLA with silicon
carbide layer
N/A 50 (30) BIOFLOW I (30) 9 0.05 0.0 CE approved
DESyne BD (Elixir
Medical)
Novolimus
(65mg/14 mm)
Co-Cr 81/<3 Abluminal PLA 6-9 90 (90) EXCELLA BD
(115)
6 0.12 0.0 CE approved
SYNERGY (Boston
Scientific)
Everolimus
(SD, 113mg/20 mm;
HD, 56mg/20 mm)
Pt-Cr 71/3 Abluminal
PLGA rollcoat
3 50 (60) EVOLVE
(SD 92; HD, 99)
6 SD, 0.10;
HD, 0.13
SD, 2.3;
HD, 1.1
CE approved
MiStent (Micell) Sirolimus (N/A) Co-Cr 64/3-5 (luminal),
10-15 (abluminal)
PLGA 3 50 (30) DESSOLVE II
(121)
9 0.27 4.9 CE approval
submitted
Excel (JW Medical
Systems)
Sirolimus
(195-376mg/stent)
SS 119/15 PLLA 6-9 N/A Registry (2077) 6 0.21 3.8 Ongoing
evaluation
Firehawk (MicroPort
Medical)
Sirolimus
(3mg/mm)
Co-Cr N/A Abluminal PDLLA
(groove-filled)
9 90 (90) TARGET I (199) 9 0.13 1.0 Ongoing
evaluation
NOYA (Medfavor
Beijing Medical)
Sirolimus
(8.8mg/mm)
Co-Cr 81/6 PDLLA N/A 80 (30) NOYA I (150) 9 0.11 4.2 Ongoing
evaluation
Inspiron (Sctech) Sirolimus
(56mg/13mm)
Co-Cr 75/5 Abluminal
PLLA+PLGA
6-9 80 (30) INSPIRON I (38) 6 0.22 3.9 Ongoing
evaluation
Tivoli (Essen
Technology)
Sirolimus
(8mg/mm)
Co-Cr 80/6 PLGA 3-6 80 (28) I-LovE-IT (168) 8 0.25 5.7 Ongoing
evaluation
BuMA (SinoMed) Sirolimus
(1.4mg/mm2)
SS 100 PLGA N/A 100 (30) PANDA-1 (113) 9 0.24 N/A Ongoing
evaluation
Svelte (Svelte) Sirolimus
(130mg/18mm)
Co-Cr 81/6 Amino acid-based
carrier coating
12 N/A DIRECT FIM (30) 6 0.15 N/A Ongoing
evaluation
CE, Conformite´ Europe´enne; Co-Cr, cobalt-chromium; HD, half dose; MB, main branch; N/A, not applicable; PCL, poly-L-lactide-co-e-caprolactone; PDLLA, poly-D, L-lactic acid; PLA, polylactic acid; PLGA, poly-lactide-co-glycolide;
PLLA, poly-L-lactic acid; Pt-Cr, platinum-chromium; PVP, poly-vinyl-pyrrolidone; SB, side branch; SD, standard dose; SS, stainless steel.
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Figure 1. The surface of the polymer-free BioFreedom stent. A scanning
electron microscopy image shows the micropores impregnated with biolimus
A9 only in the albuminal side of the strut.
T. Muramatsu et al. / Rev Esp Cardiol. 2013;66(6):483–496486late lumen loss (LLL) was 0.10 mm for SYNERGY, 0.13 mm for
SYNERGY HD, and 0.15 mm for EES (Pnoninferiority<.001). There were
no ST events in any group at up to 6-month follow-up. Recently, the
SYNERGY stent acquired the Conformite´ Europe´enne (CE) mark
approval; a pivotal EVOLVE II trial aiming a head-to-head
comparison of 12-month TLF with SYNERGY (842 patients) and
EES (842 patients) is currently ongoing.
Other Drug Eluting Stents With Biodegradable Polymers
Currently, many DES with biodegradable polymers are com-
mercially available or under clinical investigation (Table 1).
Preliminary studies have shown comparable results at 6 months
to 9 months to that of aforementioned DES with biodegradable
polymers. Although biodegradable polymers appear to have
become a promising drug-delivery technology in the newer
generation DES platform, there are issues remaining to be
addressed before their widespread clinical application.24 Further
research is needed in order to optimize the composition and
release kinetics of these polymers.
Porous Polymer-free Drug Eluting Stent
The next major step forward may be metallic stent structures
which allow for appropriate drug-elution kinetics without the
use of polymers. Several devices have been designed to test this
approach by incorporating drugs into a microporous or
nanoporous surface of the stent (Table 2). The efficacy of a
polymer-free SES (SES-PF; Yukon Choice, Translumina) was
investigated in the ISAR-TEST 3 trial.25,26 The SES-PF
(201 patients) was compared to a SES with a biodegradable
polymer (202 patients, SES-BP; Yukon Coice PC, Translumina)
and a SES with a permanent polymer (202 patients, SES-PP;
Cypher, Cordis; Miami Lakes, Florida, United States). At 2 years,
there were no significant differences in death, MI (SES-PF 6.5%,
SES-BP 5.9%, and SES-PP 6.4%), TLR (SES-PF 13.4%, SES-BP 8.4%,
and SES-PP 10.4%), and definite/probable ST (SES-PF 1.0%, SES-BP
0.5%, and SES-PP 1.0%). Patients undergoing paired angiography
at 6 months to 8 months and at 2 years (302 patients),
demonstrated a lower delayed LLL in the SES-PF (0.01 mm)
group. as compared to both the SES-BP (0.17 mm) and the
SES-PP (0.16 mm) (P<.001) groups. The absence of delayed LLL
in the SES-PF group may indicate a lower propensity for stent-
vessel wall interactions, owing to less inflammatory or
hypersensitive reactions. Recently, the 5-year clinical outcomes
in the ISAR-TEST trial have been reported.27 There were no
statistically significant differences in ST events between SES-PF
and the first generation TAXUS paclitaxel-eluting stent (PES)
(SES-PF 0.5% vs PES 1.6%, P=.32). Extended follow-up data may
further support the durability, safety, and efficacy of the SES-PF.
BioFreedom Stent
The BioFreedom stent (Biosensors Inc.). is a 316L stainless
steel, polymer-free stent that is coated with biolimus A9 (Fig. 1).
Preclinical studies have reported lower injury scores; lower
numbers of struts with fibrin, granulomas, and giant cells;
significantly lower percentage of diameter stenosis; and greater
endothelialization with the BioFreedom stent at 180-day follow-
up as compared to the Cypher SES.28 The first-in-man (FIM) trial
enrolled 182 patients who were randomized to receive either
BioFreedom with SD sirolimus (15.6 mg/mm), BioFreedom with
low dose (LD) sirolimus (7.8 mg/mm), or TAXUS Liberte´ PES. At
12 months, the in-stent LLL was 0.17 mm in the BioFreedom SDarm (P<.0001 vs PES), 0.22 mm in the BioFreedom LD arm (P=.21
vs PES), and 0.35 mm in the PES arm. There were no ST events
and no differences in major adverse cardiac events (MACE)
including all-cause death, MI, and emergent bypass surgery or
TLR at up to 36 months (BioFreedom SD 11.9%; BioFreedom LD
18.1%, and PES 10.0%).29 Currently, a randomized LEADERS FREE
trial has been planned to examine the noninferiority (a
composite of cardiac death, MI, and ST) and superiority
(clinically driven TLR) of the BioFreedom stent to BMS in
>2400 elderly patients with dual antiplatelet therapy for 1
month after stent implantation.
VESTAsync Stent
The VESTAsync stent (MIV Therapeutics; Atlanta, Georgia,
United States) combines a stainless steel platform with a
nanoporous, hydroxyapatite (biocompatible crystalline derivative
of calcium phosphate) surface coating that is impregnated with
55 mg of sirolimus mixture (Fig. 2). It is expected that sirolimus
will be completely released within the first 3 months after the
implantation, and that the hydroxyapatite will be stable over
4 months. The safety and efficacy of the VESTAsync stent was
evaluated in the VESTAsync I FIM trial. A total of 15 patients with
single de novo coronary artery lesions were enrolled. In-stent LLL
was 0.36 mm at 9 months, with no MACE reported at up to 1-year
follow-up.30 Recently a randomized VESTAsync II trial has been
reported.31 The patients treated with the VESTAsync stent
(50 patients) showed a significantly lower in-stent LLL compared
to those treated with BMS (25 patients) at 8 months (VESTAsync
0.39 mm vs BMS 0.74 mm, P=.03). No evidence of ST was reported
at up to 2-year follow-up.
Nano+ Stent
The Nano+ stent (Lepu Medical; Beijing, China) is a stainless
steel, polymer-free stent with a nanoporus surface coated with
Table 2
Overview of Polymer-free and Novel-coating Drug-eluting Stents Under Clinical Investigation or Already Available Outside the United States
Drug-eluting stent,
manufacturer
Drug, dosage Stent
platform
Strut
thickness,
mm
Surface
modification
Drug release
kinetics
Study, no.
of patients
Angiographic
follow-up,
months
In-stent late
loss, mm
Binary
restenosis, %
Current status
Porous polymer-free DES
Yukon Choice
(Translumina)
Sirolimus (11.7-21.9mg) SS 87 Abluminal microporous
surface
100%, 25 days ISAR-TEST 1 (225) 9 0.48 14.2 CE approved
BioFreedom
(Biosensors)
Biolimus A9 (SD, 15.6mg/mm;
HD, 7.8mg/mm)
SS 119 Abluminal microporous
surface
90%, 50 h FIM (SD, 31; HD, 35) 12 SD, 0.17;
HD, 0.22
N/A CE approval
submitted
VESTAsync
(MIV Therapeutics)
Sirolimus (55mg) SS 65 Nanoporous surface
with hydroxyapatite
100%, 90 days VESTAsync II (15) 8 0.39 0 Ongoing
evaluation
Nano+
(Lepu Medical)
Sirolimus (2.2mg/mm2) SS 100 Abluminal nanoporous
surface
80%, 30 days N/A N/A N/A N/A Ongoing
evaluation
DES with other technologies
Cre8 (CID) Sirolimus (0.9mg/mm2) Co-Cr 80 Abluminal reservoirs 100%, 90 days NEXT-Cre8 (162) 6 0.14 3.2 CE approved
Combo
(OrbusNeich Medical)
EPC+sirolimus (5mg/mm) SS 100/3-5 Abliminal biodegradable
polymer and luminal
CD34 antibody layer
N/A REMEDEE (124) 9 0.39 8.3 Ongoing
evaluation
FOCUS np
(Envision Scientific)
Sirolimus (108mg/16mm) Co-Cr 73 Abluminal coating with
encapsulated drug
by nanoparticles
100%, 28 days N/A N/A N/A N/A Ongoing
evaluation
CE, Conformite´ Europe´enne; Co-Cr, cobalt-chromium; SD, standard dose; DES, drug-eluting stent; EPC, endotheloal progenitor cell (capture technology); HD, half dose; N/A, not applicable; SS, stainless steel.
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Figure 2. The polymer-free VESTAsync sirolimus-eluting stent system. The scanning electron microscopy images of microporous hydroxyapatite coating (A), cross
section of the hydroxyapatite coating (B), final coating including the hydroxyapatite filled with sirolimus formulation (C), and cross section of the final coating (D).
A schematic representation of the surface coating (E).
T. Muramatsu et al. / Rev Esp Cardiol. 2013;66(6):483–496488sirolimus (2.2 mg/mm2). The average diameter of the pores is
approximately 400 nm and almost 80% of the drug is programmed
to be released within 30 days. The Bicare stent is another
nanopore-based polymer-free DES, which uses both sirolimus
and probucol. These 2 stents have a similar design, the only
difference between the Bicare stent and the Nano+ stent being
the drug type. Thirty patients with de novo lesions were enrolled in
the Bicare FIM trial.32 In-stent LLL was 0.14 mm and the rate of tissue
coverage of the struts was 98.3% determined by optical coherence
tomography (OCT) at 4 months.32 Similarly, the ISAR-TEST 5 trial
demonstrated the noninferiority of polymer-free sirolimus and
probucol-eluting stents (Yukon Choice, Translumina) over the
second generation durable-polymer resolute zotarolimus-eluting
stents (Medtronic Cardiovascular; Santa Clara, California, United
States) in terms of MACE and ST at 1-year follow-up.33A post-market
study of the Nano+ stent is currently ongoing in China, and another
trial aiming the CE mark approval has been planned in Europe.Drug Eluting Stent With Other Technologies
Cre8 Stent
The Cre8 stent (CID; Saluggia, Italy) is a polymer-free stent that
is integrally coated with an ultra-thin (0.3 mm) passive carbon
coating (i-Carbofilm, CID). The amphilimus formulation, constitut-
ed by sirolimus (0.9 mg/mm2) with an excipient composed of a
long-chain fatty acid mixture to modulate the drug release, is
loaded into abluminal reservoirs. Complete release of sirolimus
is expected within the first 3 months after stent deployment. A
total of 323 patients were randomized to receive either Cre8 (162
patients) or TAXUS Liberte´ PES (161 patients) in the NEXT FIM
trial.34 The primary endpoint was in-stent LLL at 6 months, and was
significantly lower in the Cre8 group (Cre8 0.14 mm vs PES
0.34 mm, P<.0001). A cumulative incidence of MACE including
cardiac death, MI, and TLR in the Cre8 group was 6.7% at 2 years,
Low dose sirolimus in
biodegradable polymer matrix
Lum
inal 
surfa
ce
Stent strut
Ablum
inal su
rface
Anti CD34
antibody coating
for EPC capture
EPC
CD34 Cell
surface antigen
Anti-CD34
antibody
Prosthetic surface
BA
Figure 3. The Combo dual therapy stent system. A: The Combo stent consists of an abluminal biodegradable polymer matrix with a sirolimus and a luminal CD-34
antibody layer. B: A schematic representation of the endothelial progenitor cells capture technology. The CD-34 antigens on the surface of the endothelial
progenitor cells attach to the anti-CD-34 antibodies on the stent’s surface, promoting endothelialization. EPC, endothelial progenitor cells.
T. Muramatsu et al. / Rev Esp Cardiol. 2013;66(6):483–496 489showing no differences compared to PES (7.1%). Only 1 case of
definite late ST was observed in each group at up to 2-year follow-
up.35 An all-comers registry (1000 patients) is currently ongoing
and is expected to complete enrollment of patients by early 2013.
Combo Stent
The Combo stent (OrbusNeich Medical; Hong Kong, China)
applies the endothelial progenitor cell capture technology to
enhance vessel healing (ie, immobile CD34 antibodies on the
luminal surface of the strut), incorporating abluminal LD sirolimus
and a biodegradable polymer into the current DES technology
(Fig. 3). Data from OCT and histology at 28 days in a porcine model
indicated that this hybrid stent promotes endothelialization, and
reduces neointimal formation and inflammation when compared
to the Cypher SES and the first generation Genous endothelial
progenitor cell stent.36 The REMEDEE FIM trial randomized
180 patients to treatment with either the Combo stent (124
patients) or the TAXUS Liberte´ PES (59 patients). The in-stent LLL
at 9 months was 0.39 mm in the Combo group and 0.44 mm in
the PES group (Pnoninferiority=.0012). Binary restenosis was observed
in 8.3% patients in the Combo group and in 13.5% patients in the
PES group (P=.30). No cases of ST were reported in both groups at
up to 9-months follow-up.37 Further investigation is required to
determine the prohealing effect and clinical efficacy of this device.
FOCUS np Stent
The FOCUS np stent (Envision; Surat, India) platform has a novel
carrier; a phospholipid 2-layer nanoparticle that encapsulates
sirolimus (Fig. 4). The encapsulated sirolimus is coated on the
surface of the stent and the balloon (108 mg of sirolimus on a
3.016.0 mm system). Sirolimus is programmed to be completely
released within 28 days, however, the tissue concentration of
sirolimus peakes within the first 24 h. A preclinical study with the
FOCUS np stent showed similar LLL and inflammation scores to
that seen in the Cypher SES at 28 days and at 90 days. A FIM trial
will be completed in early 2013.38
BIORESORBABLE SCAFFOLDS
Fully bioresorbable scaffolds (BRS) are a novel approach as
they provide transient vessel support in contrast to thepermanent caging caused by metallic stents. The concept of
BRS was introduced by Stack et al. in the year 1988.39 Zidar and
colleagues first implanted BRS made of poly-L-lactic acid (PLLA)
into canine femoral arteries.40 Despite significant scaffold
degradation with low-grade vascular inflammation at 9-month
follow-up, this technology failed to develop because of the inability
to manufacture an ideal polymer that could limit inflammation and
restenosis.41,42 In the year 2000, Tamai and colleagues reported their
FIM experience with BRS implantation for the treatment of human
coronary arteries.43 This ‘‘Igaki-Tamai’’ PLLA stent had a unique
zigzag helical coil design, with a strut thickness of 170 mm. This
system was self-expanding but also required balloon inflation with
heated contrast for expansion. The FIM study of the Igaki-
Tamai stent (15 patients) demonstrated no MACE or ST events
within 30 days, and 1 repeat percutaneous coronary intervention
at 6-month follow-up. Our group reported the findings of OCT at
10 years after Igaki-Tamai stent implantation, showing absence of
visible struts, with endoluminal lining of the vessel wall.44 Recently,
Nishio et al. reported >10-year clinical outcomes of the first
50 patients treated with Igaki-Tamai stents. Autopsy specimens
showed interesting histological findings, that indicated healing
with thickened neointima at the previously stented segment,
without inflammatory cell infiltration or foreign body reactions.
As measured by quantitative coronary angiography, LLL decreased
from 0.91 mm at 6 months to 0.59 mm at 3 years, whilst
intravascular ultrasound (IVUS) showed an increased external
elastic lamina area (15.0 mm2 postprocedurally and 16.9 mm2 at
3 years). These findings suggest that the artery restored its capability
to respond to expansive remodeling and late lumen enlargement
once the scaffold degraded.
Currently, numerous BRS are being tested in clinical or
preclinical studies. An overview of this technology has been
shown in Table 3 and Figure 5.
Absorbable Magnesium Stent
Magnesium (Mg) is the fourth commonest cation within
the human body. It is essential for the synthesis of over
300 enzymes, and is a cofactor for ATPase. A high dose infusion
of Mg can cause vasodilatation and the development of
collaterals during ischaemia. The degradation of Mg produces
an electronegative charge that results in the stent being
hypothrombogenic.45
Phospholipid bilayer
Hydrophilic
A B
C D
Hydrophobic
Figure 4. The nanocarrier-based FOCUS np sirolimus-eluting stent. The scanning electron microscopy (SEM) images of the crimped stent (A) and the magnified
surface of the strut and balloon (B) coated with encapsulated sirolimus (C, yellow arrows). The nanocarrier consists of a lipid bilayer with a hydrophilic head and
two lipophilic/hydrophobic tails (D), and the drug is released on pH change.
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Figure 5. Bioresorbable scaffolds under clinical or preclinical investigation.
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Table 3
Overview of Bioresorbable Scaffolds Under Current Pre-clinical or Clinical Investigation
Bioresorbable
scaffold,
manufacturer
Strut
material
Coating
material
Drug Radio-
opacity
Strut
thickness,
mm
Crossing
profile, mm
Stent-to-
artery
coverage, %
Duration of
radial support
Resorption
time, months
Angiographic
late loss, mm
(months)
Target lesio´n
revascularization
rate, % (months)
Current
status
Igaki-Tamai
(Kyoto Medical)
PLLA None None Gold
markers
170 N/A 24 6 months 24 0.48 (6) 6.7 (6) CE approved
(PAD)
AMS-1.0
(Biotronik)
Mg None None None 165 1.2 10 Days or weeks <4 1.08 (4) 45 (12) FIM
completed
AMS-3.0
(Biotronik)
Mg None Paclitaxel None 125 N/A (6 Fr
compatible)
N/A Weeks >4 0.64 (6)
0.52 (12)
4.3 (6)
4.7 (12)
FIM
(BIOSOLVE-I)
completed
AMS-4.0
(Biotronik)
Mg PLLA Sirolimus Metallic
markers
N/A N/A (6 Fr
compatible)
N/A N/A N/A N/A N/A Used in
BIOSOLVE-I
BVS 1.0
(Abbott Vascular)
PLLA PDLLA Everolimus Platinum
markers
157 1.4 26 Weeks 24 0.44 (6) 0.0 (60) FIM
completed
Absorb BVS 1.1
(Abbott Vascular)
PLLA PDLLA Everolimus Platinum
markers
157 1.4 26 6 months 24 0.19 (6)
0.27 (12)
3.6 (12) CE
approved
REVA
(REVA Medical)
Poly-tyrosine-
derived
polycaronate
polymer
None None Scaffold
itself
200 1.7 55 3-6 months 24 1.81 (6) 67 (12) FIM
completed
ReZolve
(REVA Medical)
Poly-tyrosine-
derived
polycaronate
polymer
None Sirolimus Scaffold
itself
114-228 1.5 N/A 4-6 months 24 N/A N/A FIM planned
in 2013
DESolve
(Elixir Medical)
PLLA PLLA Mvolimus Metallic
markers
150 1.5 N/A N/A 12-24 0.19 (8) 6.7 (12) FIM
completed
IDEAL BioStent
(Xenogenics)
polymer
salicylate+
linker
Salicylate Sirolimus None 175 1.5-1.7 57 3 months >12 N/A N/A FIM
completed
ART18Z (Arterial
Remodeling
Technologies)
PDLLA None None None 170 N/A (6 Fr
compatible)
<25 3-6 months 18 None None FIM
initiated
Xinsorb (Huaan
Biotechnology)
PLLA+PCL+PLGA None Sirolimus Metallic
markers
160 N/A N/A N/A N/A None None Pre-clinical
underway
Amaranth PLLA
(Amaranth Medical)
PLLA None None None 150-200 N/A (6 Fr
compatible)
N/A 3-6 months N/A None None FIM initiated
On-ABS
(OrbusNeich Medical)
PLLA+PCL+PDLLA None EPC+
sirolimus
None 150 N/A N/A N/A N/A None None Pre-clinical
underway
CE, Conformite´ Europe´enne; EPC, endothelial progenitor cell (capture technology); FIM, first-in-man; Mg, magnesium; N/A, not applicable; PAD, peripheral artery disease; PCL, poly-L-lactide-co-e-caprolactone; PDLLA, poly-D, L-
lactic acid; PLGA, poly-lactide-co-glycolide; PLLA, poly-L-lactic acid.
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T. Muramatsu et al. / Rev Esp Cardiol. 2013;66(6):483–496492The first generation absorbable metallic stent (AMS-1,
Biotronik; Berlin, Germany) was composed of 93% Mg and 7%
rare earth metals. In the porcine model, the AMS-1 was shown to
be rapidly endothelialized, and largely degraded into inorganic
salts at 60 days, with little associated inflammatory response.46
The PROGRESS AMS trial was a signle-arm FIM study, which
assessed the efficacy and safety of this stent in 63 patients with
single de novo lesions.47 No evidence of death, MI, or ST was
reported at up to 12-month follow-up. Disappointingly, the TLR rate
was 23.8% at 4 months and 45% at 12 months. The in-stent LLL was
1.08 mm and the vasodilator function, after the nitroglycerin
administration, appeared to be restored in the stented segment at
4-month angiographic follow-up.48 IVUS data suggested that the
increased LLL was attributed to an increased neointimal formation
and insufficient radial strength of the Mg alloy, due to rapid stent
degradation resulting in vessel recoil. Consequently, new stents
have been developed, namely AMS-2 and AMS-3. The AMS-2 stent
was designed to address excessive vessel recoil seen with AMS-1. It
provided prolonged mechanical integrity by using a different Mg
alloy, which not only had a higher collapse pressure, but also a
slower degradation time. In addition, the strut thickness was
reduced from 165 mm to 125 mm, and the cross-sectional shape of
the strut altered from rectangular to square. These modifications
facilitated prolonged mechanical integrity, improved radial
strength, and resulted in reduced neointimal proliferation in animal
studies. The AMS-3 stent (ie, drug-eluting AMS [DREAMS]) was
designed to incorporate a bioresorbable matrix for the controlled
release of paclitaxel with the AMS-2 platform. This device
was evaluated in the BIOSOLVE-I trial (46 patients), and demon-
strated an in-stent LLL of 0.64 mm at 6 months and 0.52 mm at
12 months. The rate of TLF was 7.0% at up to 12-month follow-up,
due to 2 clinically driven TLRs and 1 periprocedural MI.49 The
second generation DREAMS has a modified stent platform and
sirolimus as its antiproliferative drug. The BIOSOLVE-II study aimed
to assess the safety and efficacy of this device will be initiated in the
year 2013.
Everolimus-eluting Poly-L-lactic Acid Scaffold: Absorb BVS
The backbone of Absorb BVS (Abbott Vascular; Santa Clara,
California, United States) is made of PLLA. The coating consists of
poly-D, L-lactide (PDLLA), which is a random copolymer of D-lactic
acid and L-lactic acid with lower crystallinity than the backbone
PLLA. The PDLLA coating controls the release of the antiprolifera-
tive drug everolimus. The first generation Absorb BVS (1.0) was
tested in 30 patients who were enrolled in the ABSORB FIM (cohort
A) trial. Multiple modality imaging was assessed in this trial, and
the results can be summarized as follows: a) partial bioresorption
of the polymeric struts; b) late lumen enlargement between
6 months and 2 years; c) restoration of vasomotion and endothelial
function at 2 years; d) sustained scaffolding of plaque deform-
ability documented with palpography, and e) feasibility of
noninvasive imaging with multislice computed tomography.50,51
Five-year clinical follow-up is available in 29 patients.52 Only
1 patient experienced a non-Q wave MI related to the treatment of
a non-flow-limiting stenosis at 46 days after Absorb BVS
implantation. There were no ST events in the entire period and
no MACE between 6 months and 5 years, resulting in an overall
MACE rate of 3.4% at 5 years. Late scaffold shrinkage was the primary
reason for an increased in-stent LLL (0.44 mm) at 6 months. Lumen
area was reduced by 16.6%, whilst the late recoil was 11.7%.53 In
order to enhance the radial strength of the struts and to reduce late
recoil, the strut design and the manufacturing process of the
polymer were modified in the second generation Absorb BVS (1.1).
Firstly, the new design had in-phase zigzag hoops linked by bridges
that allowed for a more uniform strut distribution. This new scaffolddesign reduced maximum circular unsupported surface area that
provided for more uniform vessel wall support and drug delivery.
Secondly, a modified manufacturing process resulted in a slower
hydrolysis (in vivo degradation) rate of the polymer, thus allowing
for prolongation of its mechanical integrity.54
The Absorb BVS 1.1 was evaluated in 101 patients in the
ABSORB cohort B trial. This cohort was divided in 2 subgroups:
the first group (B1) underwent invasive imaging with quantitative
coronary angiography, IVUS, and OCT postprocedurally, at
6 months, and at 24 months; whereas the second group (B2)
underwent invasive imaging postprocedurally, at 12 months, and
at 36 months. In the entire cohort B population, the overall MACE
rate was 9.0%, including 3 non-Q wave MIs and 6 ischemia-driven
TLRs, without cardiac death during the 2-year follow-up. There
were no possible, probable, or definite scaffold thromboses despite
dual antiplatelet therapy rates of 97% at 6 months, 81.2% at
12 months, and 24.8% at 24 months.
For the cohort B1 population, serial multimodality imaging
results are currently available.55 Serial angiographic analyses
showed that in-scaffold LLL of 0.16 mm at 6 months increased to
0.27 mm at 2 years. Notably, serial IVUS analyses demonstrated
that the mean lumen area increased, whereas the minimum lumen
area remained stable between 6 months and 2 years (Fig. 6).
Percentage hyperechogenic area, a more sensitive parameter to
measure degradation of polymeric material, decreased from 25.3%
postprocedurally to 20.4% at 6 months and to 13.8% at 2 years.
Similar to IVUS, serial OCT investigation confirmed the progressive
increase in mean scaffold area from 7.47 mm2 postprocedurally, to
7.70 mm2 at 6 months, and 8.24 mm2 at 24 months.
The promising results of Absorb BVS constitute the proof of
concept that this device can adequately revascularize coronary
vessels and prevent restenosis. The Absorb BVS acquired the CE
mark approval in January 2011, and since September 2012 it is
commercially available in different diameters (2.5 mm, 3.0 mm,
and 3.5 mm) and lengths (12 mm, 18 mm, and 28 mm). This
device is now being evaluated in the ABSORB-EXTEND registry
(800 patients). A pivotal, randomized trial (ABSORB II), compar-
ing Absorb BVS with Xience Prime EES (Abbott Vascular) in
500 patients, is simultaneously ongoing in Europe.
Tyrosine Polycarbonate Stent
The REVA stent (REVA Medical, San Diego, California, United
States) consists of a tyrosine-derived poly carbonate that
degrades into water, carbon dioxide, and ethanol. In addition to
its radio-opacity, the REVA stent also has a unique ‘‘slide and lock’’
design that provides flexibility. This design maintains the acute
lumen gain following stent deployment, and provides additional
support to the scaffold during vessel remodeling. The RESORB FIM
trial enrolled 27 patients. The in-stent LLL was disappointingly
high (1.81 mm) and IVUS data showed no vessel recoil as indicated
by external elastic lamina area (15.5 mm2 postprocedurally and
15.3 mm2 at 6 months). There was a high rate of TLR (66.7%)
between 4 months and 6 months, mostly due to excessive
neointimal hyperplasia.56 The second generation ReZolve stent
had a more robust polymer, a ‘‘spiral’’ slide and lock system, and a
coating of sirolimus. Furthermore, the ReZolve2 stent had a
smaller profile (1.52 mm) and achieved approximately 30%
increase in radial strength. The safety and efficacy of the ReZolve
or ReZolve2 stent is currently under investigation in the RESTORE
study (50 patients) that was initiated in December 2011.
Preliminary data (26 patients) showed that technical success
rate was 85%, due to the delivery failure seen in 4 patients. Two
cases with TLR as a primary endpoint were reported at 6-months
follow-up.57
Post-procedure
(n=33)
IVUS measurements
Mean vessel area, (mm2)
Mean scaffold area, (mm2)
Mean plaque area, (mm2)
Mean lumen area, (mm2)
Mean NIH area, (mm2)
14.04 (3.80) 14.44 (3.82)
6.42 (1.17)
8.02 (2.89)
6.36 (1.18)
0.08 (0.13)
15.35 (4.05)
7.08 (1.73)
8.27 (2.87)
6.85 (1.78)
0.25 (0.27)
P=.008
P=.06
P=.02
P<.001
P<.001
P<.001
P=.01
P<.001
P=.03
6.53 (1.23)
6.53 (1.24)
7.51 (2.85)
6 months
(n=33)
2 years
(n=33)
Figure 6. Serial changes in intravascular ultrasound measurements over postprocedure, 6 months, and 2 years after Absorb BVS implantation. NIH, neointimal
hyperplasia. IVUS, intravascular ultrasound.
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DESolve BRS (Elixir Medical; Sunnyvale, California, United
States) has a similar PLLA backbone to the Absorb BVS, but it is
coated with myolimus (3 mg/mm), an mTOR inhibitor macrocy-
clic lactone, and a sirolimus analogue. Sufficient radial strength
was achieved over 3 months and the bioresorption of the scaffold
was observed between 1 year and 2 years. The DESolve-I FIM trial
(16 patients) demonstrated that the rate of acute recoil was 6.4%,
and in-scaffold LLL was 0.19 mm at 6 months.58 In IVUS
investigation, the respective mean scaffold area and lumen area
was 5.35 mm2 and 5.35 mm2 postprocedurally, and 5.61 mm2
and 5.10 mm2 at 6 months (P=no significant). OCT revealed that
98.7% of the struts were covered at 6 months. All patients were
clinically followed up to 1 year, and 3 patients experienced MACE
including 1 cardiac death, 1 target vessel MI, and 1 TLR. There
were no patients with the evidence of ST. The DESolve Nx trial is
currently enrolling 120 patients treated with the next generation
DESolve Nx stent with novolimus (5 mg/mm), which is an active
metabolite of sirolimus.59
Poly Salicylic Acid Stent: IDEAL
The IDEAL BRS (Xenogenics Corp.; Canton, Massachusetts,
United States) has 2 components: the backbone and the drug layer.
The backbone of the device is made of polylactide anhydride mixed
with a polymer of salicylic acid and sebacic acid linker. The drug
layer consists of salicylate that controls the release of the
antiproliferative drug sirolimus. The presence of salicylic acid
provides the device with anti-inflammatory properties, which
have been confirmed in preclinical studies.60 The IDEAL BRS was
tested in a small number of humans (11 patients) in 2008.
Although this study has not been fully reported, there was
insufficient neointimal suppression and a reduction in lumen area
due to inadequate drug dosing and rapid release of the sirolimus.61
The second generation IDEAL BioStent has a higher drug dose,
slower drug-release kinetics, and a smaller system profile. The
device is currently undergoing preclinical evaluation.
Arterial Remodeling Technologies Bioresorbable Scaffold
The ART BRS (Arterial Remodeling Technologies; Noisy le Roi,
France) is manufactured from a PDLLA amorphous polymerwithout an antiproliferative drug. This device is 6 Fr compatible,
and provides transient scaffolding for 5 months to 7 months. Full
resorption occurs within 18 months. The performance of the ART
BRS was compared with the BMS in rabbit and porcine models, and
no MACE was reported. The acute recoil was comparable to BMS.
Interestingly, angiographic analyses demonstrated the phenome-
non of late lumen enlargement, as well as increased external elastic
lamina area detected by IVUS at 9 months. Based on the results of
preclinical studies, the ARTDIVA FIM trial has already commenced
and is recruiting patients at 5 sites in France. It aims to evaluate
clinical outcomes at 6 months.62
Xinsorb Bioresorbable Scaffold
The Xinsorb BRS (Huaan Biotechnology; Laiwu, China) is a fully
bioresorbable sirolimus-loaded scaffold that consists of PLLA, poly-
lactide-co-glycolide, and poly-L-lactide-co-e-caprolactone. An
experimental study evaluated the feasibility of Xinsorb BRS in
comparison with the Excel DES (JW Medical; Shandong, China).
Sixteen Xinsorb scaffolds and 16 Excel stents were implanted in
the coronary arteries of porcine models.63 In vitro drug-elution
kinetics indicated that 78% of sirolimus was released from Xinsorb
BRS within the first 14 days. Histomorphometry demonstrated a
significantly lower percentage diameter restenosis in the Xinsorb
BRS compared to the Excel DES (18.6% vs 21.4% at 30 days and
24.5% vs 27.7% at 90 days, respectively). In addition, the struts of
the Xinsorb BRS were completely covered by neointima at
90 days.64 Although these preliminary results are encouraging,
further extensive preclinical studies are necessary to investigate
the safety and efficacy of this device. The company is expecting to
organize a FIM trial in the year 2013.
Other Brioresorbable Scaffolds
The Amaranth PLLA scaffold (Amaranth Medical; Mountain
View, California, United States) and the On-ABS (OrbusNeich, Hong
Kong, China) are currently under preclinical evaluation. In
addition, there are several other devices that are still under
development. These include the Sahajanand BRS (Sahajanand
Medical Technologies; Surat, India), the Avatar BRS (S3 V;
Hyderabad, India), the MeRes BRS (Meril Life Sciences; Vapi,
Gujarat, India), and the Zorion BRS (Zorion Medical; Indianapolis,
Indiana, United States).
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Figure 7. Schematic illustration presenting the evolution of percutaneous coronary interventions. BA, balloon angioplasty; BMS, bare metal stents; DES, drug-
eluting metallic stents; N/A, not applicable because of the absence of stent; ST, stent thrombosis; VRT, vascular reparative therapy. ‘‘+’’ implies prevented or not
restricted, whilst ‘‘’’ implies not prevented or restricted. Modified with permission from Serruys et al.67
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The new enemy in the DES era—ST—has accelerated techno-
logical evolution in interventional cardiology. Newer generation
DES, with biodegradable polymers, have shown an impressive
reduction in VLST, contributing to improved long-term outcomes,
as compared to first generation DES. The polymer-free DES or BRS
are relatively new technologies, with many trials still in progress.
The currently available angiographic, intravascular imaging, and
clinical data, suggest acceptable safety and efficacy of these new
technologies. However, it remains unclear as to whether biode-
gradable-polymer DES or polymer-free DES can minimize late ST
events, particularly as these late events have also been observed in
patients receiving BMS.65,66 Furthermore, considering the fatal
consequences of ST, focus should be maintained on the eradication,
rather than the minimization of this serious complication. There is
a fundamental difference in concept between the DES and the BRS
technologies, with the latter having a capability of liberating the
vessel from a permanent metallic cage. Therefore, BRS technology
has a theoretical advantage in reducing ST by means of
endoluminal prosthesis elimination. BRS also facilitates the
restoration of vasomotor function, which indirectly results in
the completeness of vessel healing. The entire process of this
treatment has been hence named as vascular reparative therapy
(Fig. 7).67
One possible fate of the stenotic lesion treated with metallic
stents is the development of in-stent neointimal tissue (even seen
with DES), where the antiproliferative drug slows down or
postpones the phenomenon. This neointimal tissue may in turn
become atherosclerotic, degenerate to a vulnerable plaque, and
finally rupture inside the cage of the stent (ie, neoatherosclero-
sis).68,69 A stiff metallic stent can also alter vessel geometry and
biomechanics, which may result in long-term flow disturbances
and chronic irritation, in addition to the risk of late strut fractures,
which potentially contribute to restenosis and adverse clinical
events.70,71 From a physiological perspective, the absence of a rigid
metallic cage facilitates the restoration of vasomotor function,adaptive shear stress, and late luminal enlargement. After
bioresorption, there would be no triggers for thrombosis, such
as uncovered struts or durable polymers. The absence of foreign
materials may also reduce concerns about future treatment
options, such as precluding bypass-graft surgery, and the require-
ments for long-term dual antiplatelet therapy with a potential
reduction in associated bleeding complications. Since BRS have
only been evaluated in limited patients with noncomplex lesions,
the feasibility of these devices in complex lesions requires further
clinical evaluation. In addition, future investigations are required
to establish if BRS technology is superior to permanent metallic
DES.
CONCLUSIONS
Newer metallic DES technology has proven to decrease the risk
of revascularization and ST events. The optimal design, however, of
scaffolds, polymers, antiproliferative drugs and their degradation/
release kinetics is still under investigation. BRS technology is
anticipated not only to eliminate the risk of VLST, but also to
contribute to the restoration of physiological function of treated
vessels. Although further technical development and clinical
evaluation are required before BRS can be accepted as the ultimate
device for the treatment of coronary artery disease, this new
technology looks promising and could be the next revolution in
interventional cardiology.
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